CuoripsCuorips Inc.4894東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP
It lost about ¥509 for every ¥100 of sales at the operating level. Revenue changed +21.2% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -9.3% | —× | — |
| 2023 | — | —× | -11.8% | —× | — |
| 2024 | — | —× | -10.2% | —× | — |
| 2025 | — | —× | -10.8% | —× | — |
| 2026 | — | —× | -18.8% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 14 | 38 | 23 | 175 | 212 |
| Cost of revenue | 3 | 17 | 13 | 7 | 82 |
| Gross profit | 11 | 21 | 10 | 168 | 130 |
| SG&A | 384 | 471 | 598 | 759 | 1,212 |
| Operating income | -373 | -450 | -588 | -590 | -1,081 |
| Pretax income | -373 | -450 | -630 | -642 | -1,027 |
| Income tax | 2 | 2 | 2 | 3 | 4 |
| Net income attributable to owners | -375 | -452 | -632 | -644 | -1,023 |
| Operating margin | -2682.8% | -1176.7% | -2547.3% | -336.9% | -509.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.34B | ¥2.94B | ¥5.58B | ¥4.79B | ¥3.9B |
| Total assets | ¥4.04B | ¥3.59B | ¥6.18B | ¥5.74B | ¥5.12B |
| Net assets | ¥3.9B | ¥3.45B | ¥5.98B | ¥5.53B | ¥4.77B |
| Share capital | ¥10M | ¥10M | ¥1.59B | ¥1.67B | ¥1.77B |
| Inventories | ¥10K | ¥4.7M | ¥1M | ¥45.5M | ¥64.6M |
| Property, plant and equipment | ¥633.9M | ¥562.1M | ¥514.1M | ¥514.7M | ¥502.8M |
| Intangible assets excluding goodwill | — | ¥5.5M | ¥17.1M | ¥30.3M | ¥128M |
| Current assets | ¥3.37B | ¥2.98B | ¥5.61B | ¥5.13B | ¥4.42B |
| Current liabilities | ¥112.4M | ¥97.4M | ¥166M | ¥177.3M | ¥277.5M |
| Total liabilities | ¥149.4M | ¥133.8M | ¥201M | ¥211.9M | ¥353.8M |
| Non-controlling interests | — | — | ¥1.5M | ¥2.8M | ¥18.9M |
| Equity attributable to owners of parent | ¥3.88B | ¥3.44B | ¥5.97B | ¥5.47B | ¥4.66B |
| Retained earnings | -¥1.02B | -¥1.47B | -¥2.1B | -¥2.75B | -¥3.77B |
| Treasury stock | -¥16.8M | -¥11.7M | -¥12M | -¥12.6M | -¥12.8M |
EDINET (FSA Japan)
有価証券報告書－第10期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第9期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第8期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第7期(2022/04/01－2023/03/31)
Extracted from XBRL: 45 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.